Latest Articles
NEWS CENTER Maine Weekend Morning Report at 6 a.m. - newscentermaine.com
NEWS CENTER Maine Weekend Morning Report at 6 a.m. newscentermaine.com
Published: May 16, 2026, 10 a.m.
Nuclear factor IX promotes endometriosis progression through transcriptional activation of tetraspanin-2.
Endometriosis is a benign yet aggressive disease characterized by enhanced proliferation and invasion of ectopic endometrial tissue. Identifying upstream regulators that co-regulate these processes will provide novel insights into endometriosis …
Published: May 16, 2026, midnight
Pete Davidson and Elsie Hewitt Reportedly Split 5 Months After Welcoming First Child Together - AOL.com
Pete Davidson and Elsie Hewitt Reportedly Split 5 Months After Welcoming First Child Together AOL.com
Published: May 15, 2026, 2:44 p.m.
Pete Davidson and Elsie Hewitt Reportedly Split 5 Months After Daughter's Birth, Insider Says They're "Working on Things" - Yahoo News Singapore
Pete Davidson and Elsie Hewitt Reportedly Split 5 Months After Daughter's Birth, Insider Says They're "Working on Things" Yahoo News Singapore
Published: May 15, 2026, 2:44 p.m.
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart
Published: May 14, 2026, 4:30 p.m.
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis - Newswise
Maipl Therapeutics Reports Preclinical Progress for MA-4604, a Novel Oral Non-Hormonal Treatment of Endometriosis Newswise
Published: May 14, 2026, 12:40 p.m.
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M - TradingView
Karyopharm Therapeut Reports Q1 2026: $35.1M Revenue, $29.2M U.S. Product Sales, Net Loss $22.4M TradingView
Published: May 14, 2026, 11:33 a.m.
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire
Published: May 14, 2026, 11:30 a.m.
Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - Moomoo
Press Release: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Moomoo
Published: May 14, 2026, 11:30 a.m.
Giant endometrioma of the canal of nuck mimicking a vulvar mass: a rare case and narrative review.
Endometriosis of the canal of Nuck is an extremely rare manifestation of extrapelvic endometriosis that may mimic common groin pathologies such as inguinal hernia or hydrocele, often leading to diagnostic …
Published: May 14, 2026, midnight
Link copied to clipboard!